Product Code THZ-SDP-99 refers to the chiral small molecule (S)-2,6-Dipropionamido-4,5,6,7-tetrahydrobenzothiazole, supplied as a crystalline powder with a minimum purity of 98.5% and enantiomeric excess typically exceeding 99.0%. The compound carries a single stereogenic center at the 6-position of the partially saturated benzothiazole bicycle, and the two propionamide substituents at the 2- and 6-positions provide both hydrogen-bonding donor and acceptor functionality. This combination of a constrained thiazole pharmacophore with directional amide vectors makes the molecule a favored intermediate in fragment-based drug discovery programs targeting kinase hinge regions where chirality dictates binding pocket complementarity. Standard lot release includes assay by HPLC at 254 nm (USP 621), chiral purity by SFC on amylose tris(3,5-dimethylphenylcarbamate) stationary phase, residual solvent profile by headspace GC (USP 467), and water content by coulometric Karl Fischer titration (ASTM D1364, limit ≤0.5% w/w).
In synthetic chemistry workflows targeting enantioselective C–N bond formation, the homochiral tetrahydrobenzothiazole scaffold has been used to prepare constrained peptidomimetics and sulfonamide-based inhibitors. The (S)-enantiomer exhibits a specific rotation [α]D20 of +34° ± 2° (c=1.0, MeOH), a melting endotherm onset at 178–181 °C determined by differential scanning calorimetry under nitrogen purge at 10 K/min (ASTM E794), and a calculated logP of 1.9. These values distinguish it from the (R)-antipode, which rotates light at -33° under identical conditions and packs in a centrosymmetric space group, altering its dissolution rate in aqueous media by approximately 18% relative to the (S)-form due to differences in crystal lattice energy. The product is supplied in amber glass vials under argon headspace, double-bagged with desiccant, and shipped with a Certificate of Analysis referencing the batch-specific internal standard.
What Limits the Utility of Non-Chiral Tetrahydrobenzothiazoles?
Racemic 2,6-disubstituted tetrahydrobenzothiazoles, while commercially accessible at lower cost, introduce diastereomeric mixtures when elaborated into larger constructs containing additional stereocenters. This complicates crystallization-driven purification and generates complex HPLC traces that confound in-process control. In one published fragment elaboration campaign, switching from racemic 2-amino-6-propionamido-4,5,6,7-tetrahydrobenzothiazole to the single (S)-enantiomer reduced the required number of preparative chromatographic steps from three to one, while increasing the overall isolated yield from 14% to 41% over four synthetic stages. The chiral integrity of the 6-position is maintained under conditions of pH 2–9 at 25 °C for 72 h, with racemization only observed upon extended exposure to strong bases (DBU, >0.5 M) at temperatures exceeding 60 °C, a limitation stemming from enolization of the propionamide carbonyl.
When the (S)-enantiomer is incorporated into intermediates destined for palladium-catalyzed cross-coupling at the 5- or 7-position of the tetrahydrobenzothiazole core, the amide N–H groups require protection, typically as tert-butylcarbamates, to avoid catalyst poisoning. In this context, the product differs from analogous 2-aminothiazoles where the 2-amino group is converted to a sulfonamide prior to coupling; the propionamide’s lower nucleophilicity allows for a broader selection of unprotected transformations, including Buchwald–Hartwig aminations using XPhos Pd G3 at 2 mol% loading.
| Compound | 6-Substituent | Chiral | Melting Range (°C) | HPLC Purity Standard | Typical ee (%) | Common Application |
|---|---|---|---|---|---|---|
| (S)-2,6-Dipropionamido-4,5,6,7-THB | -NHCOEt | Yes | 178–181 | USP 621 | 99.2% | Chiral hinge-binding motifs |
| 2-Amino-6-propionamido-4,5,6,7-THB (racemic) | -NHCOEt | No | 162–168 dec. | USP 621 | N/A | Early-stage library synthesis |
| (R)-2,6-Dipropionamido-4,5,6,7-THB | -NHCOEt | Yes | 177–180 | USP 621 | 99.0% | Opposite chirality probe |
| 2-Acetamido-6-amino-4,5,6,7-THB | -NH₂ | No | 195–197 | Ph.Eur. 2.2.29 | N/A | Achiral scaffold diversification |
When Humidity Exceeds 60% RH in Dispensing Rooms
The primary handling challenge arises from the compound’s hygroscopicity at relative humidity above 60%. Dynamic vapor sorption analysis shows a mass increase of 2.1% w/w between 50% and 80% RH at 25 °C, causing particle agglomeration and compromised dispensing accuracy on automated powder-handling platforms such as a Chemspeed SWING. In manufacturing suites operating under ISO 14644-1 Class 8 conditions, the product must be pre-dried in a vacuum oven set to 40 °C and <10 mbar for a minimum of 4 h prior to formulation, with a nitrogen-purged glovebox maintaining an internal dew point below -40 °C. Attempts to mill the dried material using a Fritsch Pulverisette at 15,000 rpm without cryogenic cooling resulted in agglomerate reformation due to frictional heating that raised the powder temperature to 38 °C within 90 s, underlining the necessity of integrated temperature control.
Differences from more robust achiral thiazoles become pronounced under these conditions. The parent 2-amino-4,5,6,7-tetrahydrobenzothiazole hydrochloride can be handled in ambient air with no measurable weight gain over 24 h. The (S)-dipropionamido derivative’s susceptibility originates from the dual amide groups that form hydrogen-bonded networks with water, a property that, while undesirable in dispensing, becomes advantageous in biological environments where improved aqueous solubility relative to the methyl ether analog is observed: 1.2 mg/mL in phosphate-buffered saline at pH 7.4 versus 0.08 mg/mL for the corresponding 2-methoxy compound.
A Question of Residual Palladium in Advanced Intermediates
During scale-up of the enantioselective hydrogenation step used to establish the 6-position stereocenter, the choice of catalyst—(R,R)-Ts-DENEB Rhodium(I) complex immobilized on silica—introduces a catalyst carryover risk. While the crude product typically contains 450–800 ppm rhodium after solvent stripping, the subsequent hot filtration through a Celite pad and recrystallization from isopropanol/water (7:3) reduces the residual metal content to below 20 ppm by ICP-OES (USP 233), meeting the ≤25 ppm limit stipulated in the ICH Q3D Guideline for oral drug substances. In contrast, the alternative route employing BINAP-ruthenium catalysts, while offering a slightly higher diastereoselectivity (99.5% de vs. 99.0% de), necessitates a subsequent metal scavenging step with functionalized silica (Si-Thiol) that increases process mass intensity by 35% and risks product loss through irreversible adsorption. Published data for this specific configuration of the tetrahydrobenzothiazole core with BINAP-Ru systems remains limited, discouraging their use in cGMP sequences.
When the compound is intended for preparative chiral chromatography as an alternative to asymmetric hydrogenation, the separation factor (α) between the (S)- and (R)-enantiomers on a Chiralpak IG column (250 × 4.6 mm, 5 µm) with hexane/ethanol/diethylamine (80:20:0.1) mobile phase at 1.0 mL/min is 1.42, enabling collection of the (S)-enantiomer with 99.8% ee after a single pass at a loading of 200 mg per injection. This preparative resolution route eliminates the heavy metal burden entirely, making it attractive for preclinical programs where even sub-ppm Rh exposure must be avoided in cellular assays. The downside is a throughput limitation; at pilot scale, the hydrogenation route delivers 12 kg batches per week on a Parr 50 L reactor, whereas the SMB chromatography setup yields 1.1 kg per week on a 50 mm ID column set.
Storage stability data over 36 months at -20 °C under argon indicate <0.1% degradation per annum measured by total impurities. When held at 25 °C/60% RH open-dish for 7 days, the main degradant observed by LC-MS is the 2-propionamido hydrolysis product (m/z 213.1), reaching 0.9 area%. Comparative forced degradation of the simple 2-amino-6-methyl tetrahydrobenzothiazole under identical conditions shows oxidative dimerization at the amino group, a pathway that is blocked in the dipropionamido analog due to amide resonance stabilization. This stability profile supports the (S)-2,6-Dipropionamido-4,5,6,7-tetrahydrobenzothiazole as a reliably storable building block across multi-year discovery timelines, provided that strict control of moisture and headspace oxygen is maintained.
The compound’s ultraviolet absorption maximum at 262 nm (ε = 9,800 L mol⁻¹ cm⁻¹) allows sensitive detection during UPLC purity monitoring, a practical distinction from certain 4,5,6,7-tetrahydrobenzothiazole esters that lack a strong chromophore above 220 nm. This simplifies method transfer between analytical and preparative scales and aligns with the typical diode-array detection windows installed in pharmaceutical quality control laboratories operating under 21 CFR Part 11 compliant chromatography data systems.
Why the 2-Propionamide Motif Over Methyl or Phenyl Analogues?
Replacing the propionamide group at the 2-position with an acetamide, benzamide, or simple amine alter the molecule’s hydrogen-bonding capacity and metabolic liability. Acetamide derivatives exhibit similar potency in enzymatic inhibition assays but suffer from higher susceptibility to hepatic esterases, with human liver microsome stability half-lives below 12 min in the presence of NADPH. The propionamide adds a single methylene unit, increasing LogD by approximately 0.5 units and prolonging the half-life to 38 min under the same conditions. The benzamide analogue, while metabolically stable (>b>60 min), reduces solubility to <0.02 mg/mL and introduces planarity that promotes cytochrome P450 3A4 inhibition (IC₅₀ = 0.8 µM). Thus, the (S)-2,6-dipropionamido substitution pattern represents a balanced choice for parallel optimization of solubility, metabolic stability, and off-target pharmacology risk.
When the product is incorporated into a series targeting a kinase displaying selectivity for the (S)-configuration over the (R)-configuration by a factor of 55-fold in IC₅₀, the chiral purity of the intermediate directly correlates with the potency window between target and anti-target. A drop in ee from 99% to 95%—i.e., an (R)-enantiomer impurity of 2.5% versus 0.5%—can reduce the selectivity ratio to 9-fold, crossing the threshold of acceptable kinase panel selectivity for advancement beyond lead optimization. Controlling enantiomeric purity at the building block stage via the specifications of THZ-SDP-99 thereby becomes a critical quality attribute traceable directly to the downstream biological fingerprint.
